Javascript must be enabled to continue!
Supervillin-mediated ZO-1 downregulation facilitates migration of cisplatin-resistant HCT116 colorectal cancer cells
View through CrossRef
Abstract
Supervillin (SVIL), the biggest member of the villin/gelsolin superfamily, has recently been reported to promote the metastasis of hepatocellular carcinoma by stimulating epithelial-mesenchymal transition (EMT). However, data about the role of SVIL in the migration of colorectal cancer cells are scarce. We investigated the effects of SVIL on the migration of cisplatin-resistant colorectal cancer cells. The model of cisplatin-resistant HCT116 cells (HCT116/DDP) was established. SVIL-knockdown HCT116/DDP cells with virus infection were also used. Migration was assessed by transwell assay and wound healing assay, tumor metastasis was assessed using a mouse model with tail vein injection of colorectal cancer cells. The results showed that the expression of SVIL was upregulated in HCT116/DDP cells compared to their parental cells. Also, the HCT116/DDP cells showed increased cell migration, stemness and lung metastasis. Furthermore, we revealed that the up-regulated SVIL was associated with the induction of migration of HCT116/DDP cells. Reduced SVIL expression reversed the enhanced migration and lung metastasis in cisplatin-resistant colorectal cancer cells. Further work showed that SVIL silencing reduced cell migration by targeting zona occludens (ZO)-1 mediated tight-junction remodeling. The expression of ZO-1, but not occludin and cludin5, was down-regulated after SVIL knock-down. Fluorescence detection indicated that the linear ZO-1 expression was interrupted in HCT116/DDP cells while the SVIL silencing reversed the interruption. This study firstly displayed the relationship between SVIL and ZO-1 in cisplatin-resistant colon cancer cells, providing a new insight into the mechanism of colorectal cancer migration.
Research Square Platform LLC
Title: Supervillin-mediated ZO-1 downregulation facilitates migration of cisplatin-resistant HCT116 colorectal cancer cells
Description:
Abstract
Supervillin (SVIL), the biggest member of the villin/gelsolin superfamily, has recently been reported to promote the metastasis of hepatocellular carcinoma by stimulating epithelial-mesenchymal transition (EMT).
However, data about the role of SVIL in the migration of colorectal cancer cells are scarce.
We investigated the effects of SVIL on the migration of cisplatin-resistant colorectal cancer cells.
The model of cisplatin-resistant HCT116 cells (HCT116/DDP) was established.
SVIL-knockdown HCT116/DDP cells with virus infection were also used.
Migration was assessed by transwell assay and wound healing assay, tumor metastasis was assessed using a mouse model with tail vein injection of colorectal cancer cells.
The results showed that the expression of SVIL was upregulated in HCT116/DDP cells compared to their parental cells.
Also, the HCT116/DDP cells showed increased cell migration, stemness and lung metastasis.
Furthermore, we revealed that the up-regulated SVIL was associated with the induction of migration of HCT116/DDP cells.
Reduced SVIL expression reversed the enhanced migration and lung metastasis in cisplatin-resistant colorectal cancer cells.
Further work showed that SVIL silencing reduced cell migration by targeting zona occludens (ZO)-1 mediated tight-junction remodeling.
The expression of ZO-1, but not occludin and cludin5, was down-regulated after SVIL knock-down.
Fluorescence detection indicated that the linear ZO-1 expression was interrupted in HCT116/DDP cells while the SVIL silencing reversed the interruption.
This study firstly displayed the relationship between SVIL and ZO-1 in cisplatin-resistant colon cancer cells, providing a new insight into the mechanism of colorectal cancer migration.
Related Results
Abstract 1761: Dual inhibition of HSP27 and FAO as a novel therapeutic strategy for cisplatin-resistant ovarian cancer
Abstract 1761: Dual inhibition of HSP27 and FAO as a novel therapeutic strategy for cisplatin-resistant ovarian cancer
Abstract
Cisplatin is the most commonly employed chemotherapeutic drug for ovarian cancer treatment. However, most ovarian cancer patients experience recurrent cispl...
Abstract 1490: RAD51C-deficient cancer cells require DNA polymerase zeta to bypass cisplatin-induced lesion
Abstract 1490: RAD51C-deficient cancer cells require DNA polymerase zeta to bypass cisplatin-induced lesion
RAD51C is a RAD51 paralog protein that mediates RAD51 filament formation on single-stranded DNA (ssDNA) in a canonical homologous recombination (HR) pathway. This step is vital for...
The Pivotal Role of PAO in CDK Inhibitors (Roscovitine and Purvalanol)- Triggered Apoptosis in PUMA Null HCT116 Colon Cancer Cells
The Pivotal Role of PAO in CDK Inhibitors (Roscovitine and Purvalanol)- Triggered Apoptosis in PUMA Null HCT116 Colon Cancer Cells
Background: Cycline-dependent kinase inhibitors (CDKi); roscovitine and purvalanol, are promising anti-cancer drugs due to their strong anti-proliferative effectiveness due to acti...
Abstract 1557: Overexpressions of ALEX1 gene play a negative role in human colorectal tumorigenesis
Abstract 1557: Overexpressions of ALEX1 gene play a negative role in human colorectal tumorigenesis
Abstract
Background: Arm protein lost in epithelial cancers, on chromosome X (ALEX) is a novel subgroup within the armadillo family which has several ARM repeat doma...
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract
Introduction: Current study found that about one-third of the incidence of colorectal cancer have genetic related. Hereditary nonpolyposis colorectal cancer...
Abstract 232: Cancer stem cells and cisplatin.
Abstract 232: Cancer stem cells and cisplatin.
Abstract
Introduction:
Cisplatin is an important chemotherapeutic agent, which has resulted in higher overall response rates when combined with 5-FU o...
Data from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
Data from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
<div>Abstract<p><b>Purpose:</b> Ovarian cancer has the highest mortality rate of all female reproductive malignancies. Drug resistance is a major cause of t...
Data from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
Data from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
<div>Abstract<p><b>Purpose:</b> Ovarian cancer has the highest mortality rate of all female reproductive malignancies. Drug resistance is a major cause of t...

